Needham & Company analyst Chad Messer reiterated a Buy rating and $26 price target on ISIS Pharmaceuticals (NASDAQ: ISIS) following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE